Regression of brain metastases from breast cancer with eribulin: a case report

BMC Research Notes

Kazuhiko Nakagawa²  Atsuko Koyama²  Yoshifumi Komoike¹  Tsutomu Iwasa²  Junko Tanizaki²  Junji Tsurutani²  Hiromichi Matsuoka² 

[1] Department of Breast and Endocrine Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan;Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan

关键词: P-glycoprotein;    Brain metastases;    Eribulin;    Blood brain barrier;    Breast cancer;   

Others  :  1137130
DOI  :  10.1186/1756-0500-6-541

 received in 2013-08-15, accepted in 2013-12-13,  发布年份 2013

【 摘 要 】

Background

Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for patients with advanced breast cancer. Although there have been several case reports describing the efficacy of capecitabine against brain metastases, no report of eribulin demonstrating efficacy for brain metastases exists today.

Case presentation

We describe a case of a 57-year-old Japanese woman who was diagnosed with breast cancer stage IV metastasized to multiple organs including liver and lung. After she received 3 regimens, she showed evidence of brain metastases, and whole brain radiation therapy was performed. Lapatinib and capecitabine was then administered as fourth-line chemotherapy, but the patient was hospitalized due to the exacerbation of interstitial pneumonitis and progression of brain and liver metastases. To control the systemic disease, eribulin was commenced as fifth-line chemotherapy. One month later, a significant response of brain metastases had been achieved, and this response has persisted for the last 4 months. We now describe a remarkable antitumor effect of eribulin against brain metastases from breast cancer. This case is the first report which indicates potential treatment of brain metastases using this medication.

Conclusion

This report suggests that eribulin treatment may be beneficial for breast cancer patients with brain metastases progressing after whole brain radiation therapy. However, further clinical studies are warranted to determine the clinical effect of eribulin in brain metastases.

【 授权许可】

   
2013 Matsuoka et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S: A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012, 23:1441-1448.
• [2]Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 23:914-923.
• [3]Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J of Clin Oncol 2010, 28:3922-3928.
• [4]Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J of Clin Oncol 2009, 27:2954-2961.
• [5]Hawkins BT, Davis TP: The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185.
• [6]Taur JS, DesJardins CS, Schuck EL, Wong YN: Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2cells. Xenobiotica 2011, 41:320-326.
• [7]Yu MJ, Zheng W, Tendyke K: Atom-based enumeration: new eribulin analogues with low susceptibility to P-glycoprotein-mediated drug efflux. Bioorg Med Chem Lett 2012, 15:7363-7366.
• [8]Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci U S A 1989, 86:695-698.
• [9]Ueno M: Mechanisms of the penetration of blood-borne substances into the brain. Curr Neuropharmacol 2009, 7:142-149.
• [10]Bart J, Nagengast WB, Coppes RP, Wegman TD, van der Graaf WT, Groen HJ, Vaalburg W, de Vries EG, Hendrikse NH: Irradiation of rat brain reduces p-glycoprotein expression and function. Br J Cancer 2007, 97:322-326.
• [11]De Angelis LM, Posner JB, Posner JB: Neurologic complications of cancer. 2nd edition. Oxford, New York: Oxford University Press; 2009:634.
• [12]Gerstner ER, Fine RL: Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J of Clin Oncol 2007, 25:2306-2312.
• [13]Wunder A, Schoknecht K, Stanimirovic DB, Prager O, Chassidim Y: Imaging blood–brain barrier dysfunction in animal disease models. Epilepsia 2012, 53:14-21.
• [14]Easton AS: Regulation of permeability across the blood–brain barrier. Adv Exp Med Biol 2012, 763:1-19.
• [15]Nieder C, Aandahl G, Dalhaug A: A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Rep Oncol Med 2012, 2012:537183. doi:10.1155/2012/537183. Epub 2012 Aug 16